Haematopoietic Stem Cell Transplantation for Relapsing-Remitting Multiple Sclerosis in Sweden
A study from Sweden analyzed 174 patients with relapsing-remitting multiple sclerosis (RRMS) treated with autologous haematopoietic stem cell transplantation (aHSCT). The results showed that 73% of patients had no evidence of disease activity (NEDA) at five years, with over half experiencing improvement in disability. The findings support the potential role of aHSCT as a treatment option for highly active RRMS.
